Evidence map›Paper›PMID 41808707›Full record

ArticleTranslational lung cancer research2026

Molecular epidemiology and outcomes of

Shinkyo Yoon, Seong-Eun Kim, Sun Min Lim, Hyun Ae Jung, Kyu-Pyo Kim, Dong-Kyu Kim, Hyehyun Jeong, Subin Lim, Jung-Ae Kim, Joohyun Kim and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shinkyo Yoon *Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.ORCID https://orcid.org/0000-0001-7544-0404
Seong-Eun Kim *Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.ORCID https://orcid.org/0009-0000-2584-3870
Sun Min LimDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Hyun Ae JungDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Kyu-Pyo KimDepartment of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Dong-Kyu KimReal-World Evidence Team, ALYND, Yonsei University Health System, Seoul, South Korea.
Hyehyun JeongDepartment of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Subin LimReal-World Evidence Team, ALYND, Yonsei University Health System, Seoul, South Korea.
Jung-Ae KimIQVIA Solutions Korea Ltd., Seoul, South Korea.
Joohyun KimIQVIA Solutions Korea Ltd., Seoul, South Korea.
Dony PatelIQVIA Real-World Solutions Global, London, UK.
Xiahong ZhaoIQVIA Solutions Asia Pte Ltd., Singapore, Singapore.
Dae Young YuJanssen Korea, Seoul, South Korea.
Ji Hyun KimJanssen Korea, Seoul, South Korea.
Dae Ho LeeDepartment of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The treatment landscape for metastatic or advanced non-small cell lung cancer (aNSCLC) evolved with the development of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs). However, Methods: Electronic medical records (EMRs) from three major hospitals in South Korea were analyzed retrospectively. Patients diagnosed with aNSCLC and confirmed Results: Among 2,209 patients with aNSCLC, 1,978 (89.5%) exhibited common Conclusions: E20ins represents a small but significant subset of

Indexed as

epidermal growth factor receptor (EGFR)exon 20 insertion (E20ins)next-generation sequencing (NGS)Non-small cell lung cancer (NSCLC)tyrosine kinase inhibitors (TKIs)

Identifiers

PMID41808707
PMCPMC12969239

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.